An orphan designation may add value to a product by potentially increasing stock value, increasing the company visibility, and initiating early interactions with Health Authorities. However, seeking an orphan designation too early has its disadvantages, including public disclosure of regulatory strategy, product positioning, and risking a premature application with a following rejection due to insufficient data. As a result, when to submit an ODD is subject to particular consideration. This paper explores how to optimize this process.
You may also be interested in:
Page
Global Regulatory Affairs
PRA’s Global Regulatory Affairs (GRA) group brings more than 20 years’ experience navigating the complex regulatory environment. We leverage our…
Blog
Navigating Global Regulatory CMC Processes During Public Health Crises
Chemistry, manufacturing, and controls (CMC) regulations are a critical part of the drug development path and the ongoing production and distribution…
White Paper
European Union Medical Devices Regulation: Electronic Labeling
The May 2017 release of a new MDR in the Official Journal of the European Union marked the start of a three-year transitional period within the…